# A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment

> **NCT07104162** · PHASE1 · RECRUITING · sponsor: **Qpex Biopharma, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Cefiderocol/Xeruborbactam

## Key facts

- **NCT ID:** NCT07104162
- **Lead sponsor:** Qpex Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-16
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-12-23
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07104162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07104162, "A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07104162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*